Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""van Oort, I. M."" wg kryterium: Autor


Tytuł :
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Autorzy :
Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands. .; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands. .
Kuppen MCP; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
Bergman AM; Division of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van Moorselaar RJA; Department of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
Coenen JLLM; Department of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands.
van den Bergh ACM; Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Somford DM; Department of Urology, Canisius Wilhemina Hospital, Nijmegen, the Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
Aben KKH; Department for Health Evidence, Radboud University Medical Center, The Netherlands and Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
Pokaż więcej
Źródło :
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2021 Mar 21. Date of Electronic Publication: 2021 Mar 21.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Autorzy :
Boerrigter E; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Benoist GE; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
van Oort IM; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Verhaegh GW; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
van Hooij O; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Groen L; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Smit F; MDxHealth, Nijmegen, The Netherlands.
Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands.
de Mol P; Department of Medical Oncology, Gelderse Vallei Hospital, Ede, The Netherlands.
Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Mehra N; Deparment of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands.
Schalken JA; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
van Erp NP; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 Mar 02. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study.
Autorzy :
van Santvoort BWH; Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
van Leenders GJLH; Department of Pathology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Kiemeney LA; Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
van Oort IM; Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
Wieringa SE; Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Jansen H; Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Vernooij RWM; Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Hulsbergen-van de Kaa CA; Laboratory of Pathology East-Netherlands, Hengelo, the Netherlands.
Aben KKH; Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.; Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Scandinavian journal of urology [Scand J Urol] 2020 Dec; Vol. 54 (6), pp. 463-469. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies